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Jin et al. show that mitochondrial
glutaminolysis contributes to redox
homeostasis through glutamate
dehydrogenase 1 (GDH1) regulation of
a-ketoglutarate, fumarate, and GPx1.
GDH1 is upregulated in human cancers,
and its inhibition perturbs redox
homeostasis and attenuates cancer cell
proliferation and tumor growth.
Cancer Cell
ArticleGlutamate Dehydrogenase 1 Signals
through Antioxidant Glutathione Peroxidase 1
to Regulate Redox Homeostasis and Tumor Growth
Lingtao Jin,1 Dan Li,1 Gina N. Alesi,1 Jun Fan,1 Hee-Bum Kang,1 Zhou Lu,2,10 Titus J. Boggon,3 Peng Jin,4 Hong Yi,5
Elizabeth R. Wright,6 Duc Duong,7 Nicholas T. Seyfried,7 Robert Egnatchik,8 Ralph J. DeBerardinis,8 Kelly R. Magliocca,9
Chuan He,2 Martha L. Arellano,1 Hanna J. Khoury,1 Dong M. Shin,1 Fadlo R. Khuri,1 and Sumin Kang1,*
1Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
2Department of Chemistry and Institute for Biophysical Dynamics, The University of Chicago, Chicago, IL 60637, USA
3Department of Pharmacology, Yale University, New Haven, CT 06520, USA
4Department of Human Genetics, Emory University, Atlanta, GA 30322, USA
5Robert P. Apkarian Integrated Electron Microscopy Core, Emory University, Atlanta, GA 30322, USA
6Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
7Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA
8UT Southwestern Medical Center, Dallas, TX 75390, USA
9Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
10Present address: School of Pharmacy, Fudan University, Shanghai 201203, China
*Correspondence: smkang@emory.edu
http://dx.doi.org/10.1016/j.ccell.2014.12.006SUMMARYHowmitochondrial glutaminolysis contributes to redox homeostasis in cancer cells remains unclear. Here we
report that themitochondrial enzyme glutamate dehydrogenase 1 (GDH1) is commonly upregulated in human
cancers. GDH1 is important for redox homeostasis in cancer cells by controlling the intracellular levels of its
product alpha-ketoglutarate and subsequent metabolite fumarate. Mechanistically, fumarate binds to and
activates a reactive oxygen species scavenging enzymeglutathione peroxidase 1. TargetingGDH1 by shRNA
or a small molecule inhibitor R162 resulted in imbalanced redox homeostasis, leading to attenuated cancer
cell proliferation and tumor growth.INTRODUCTION
Emerging evidence indicates that impaired cellular metabolism
is the defining characteristic of nearly all cancers regardless of
cellular or tissue origin (Hsu and Sabatini, 2008). One predomi-
nant metabolic abnormality is that cancer cells take up glucose
at higher rates than normal tissue and favor aerobic glycolysis
(Kim and Dang, 2006; Warburg, 1956). In addition to the depen-
dency on glycolysis, cancer cells have another atypical
metabolic characteristic, that of increased rates of glutamine
metabolism. Although the requirement for mitochondrial ATP
production is reduced in glycolytic tumor cells, the demand for
tricarboxylic acid cycle (TCA) cycle-derived biosynthetic precur-Significance
Our findings provide insight into understanding the role of g
GDH1 predominantly controls the intracellular levels of alpha-k
homeostasis. Moreover, our findings also suggest a signaling f
allowing additional crosstalk between glutaminolysis, tricarbox
R162 demonstrated promising efficacy and minimal toxicity
in vivo, as well as in primary leukemia cells from human patien
GDH1 as a promising therapeutic target in the treatment of hum
Csors and nicotinamide adenine dinucleotide phosphate, reduced
form (NADPH) is unchanged or even increased (Frezza and Got-
tlieb, 2009). In order to compensate for these changes and
to maintain a functional TCA cycle, cancer cells often rely on
elevated glutaminolysis.
Glutaminolysis is a mitochondrial pathway that involves the
initial deamination of glutamine by glutaminase (GLS), yielding
glutamate and ammonia. Glutamate is then converted to
alpha-ketoglutarate (a-KG), a TCA cycle intermediate, to pro-
duce both ATP and anabolic carbons for the synthesis of amino
acids, nucleotides, and lipids (DeBerardinis et al., 2007; Lu et al.,
2010; Medina, 2001; Moreadith and Lehninger, 1984; Reitzer
et al., 1979; Wise and Thompson, 2010). The conversion oflutaminolysis in redox homeostasis. We demonstrated that
etoglutarate in cancer cells and plays a crucial role in redox
unction of fumarate that regulates glutathione peroxidase 1,
ylic acid cycle, and redox status. Finally, our GDH1 inhibitor
in the treatment of diverse human cancer cells in vitro and
ts. Thus, our findings provide proof of principle suggesting
an cancers associated with elevated glutamine metabolism.
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glutamate to a-KG is catalyzed by either glutamate dehydroge-
nase 1 (GDH1, also known as GLUD1, GLUD, GDH) or other
transaminases, including glutamate pyruvate transaminase 2
(GPT2, also known as alanine aminotransferase), and glutamate
oxaloacetate transaminase 2 (GOT2, also known as aspartate
aminotransferase), which convert a-keto acids into their corre-
sponding amino acids in mitochondria (Kovacevic, 1971; Qua-
gliariello et al., 1965). Fluxes of these enzymes are commonly
elevated in human cancers (Friday et al., 2011). Glutaminolysis
also supports the production of molecules, such as gluta-
thione and NADPH, which protect cells from oxidative stress
(DeBerardinis and Cheng, 2010; Reitzer et al., 1979; Wise and
Thompson, 2010). Mounting evidence suggests that many types
of cancer cells have tumor-specific redox control alterations,
with increased levels of reactive oxygen species (ROS)
compared with normal cells (Kawanishi et al., 2006; Stuart
et al., 2014; Szatrowski and Nathan, 1991; Toyokuni et al.,
1995). Amoderate increase in ROS can promote cell proliferation
and differentiation (Boonstra and Post, 2004), whereas exces-
sive amounts of ROS can cause oxidative damage to proteins,
lipid, and DNA (Perry et al., 2000). Therefore, maintaining ROS
homeostasis is crucial for cell growth and survival. Cells control
ROS levels by balancing ROSgeneration with their elimination by
ROS-scavenging systems such as glutathione peroxidase (GPx),
gluthathione reductase (GSR), thioredoxin (Trx), superoxide
dismutases (SODs), catalase (CAT), and peroxiredoxin (PRX).
a-KG, a product of GDH1 and a key intermediate in glutamine
metabolism, is known to stabilize redox homeostasis in cells
(Niemiec et al., 2011). Although elevated glutaminolysis and
altered redox status in cancer cells has been theoretically justi-
fied, themechanism bywhich a-KG regulates redox andwhether
this regulation is crucial for tumorigenesis and tumor growth
remain elusive.
RESULTS
GDH1 Predominantly Regulates a-KG Production in
Cancer Cells and Is Upregulated in Human Cancers
To better understand the role of glutamine metabolism in human
cancers, we tested the effect of blocking the conversion of gluta-
mate to a-KG, a crucial step in glutaminolysis, on cancer cells.
Among the three enzymes that may regulate this step, we found
that GDH1 is the enzyme predominantly responsible for the con-
version of glutamate to a-KG compared with the other two mito-
chondrial enzymes, GOT2 and GPT2, in lung cancer H1299 cells
and breast cancer MDA-MB231 cells (Figure 1A). Moreover,
shRNA-mediated stable knockdown of GDH1 resulted in a
significantly attenuated glutaminolysis rate compared with that
in control cells harboring an empty vector (Figure 1B), suggesting
a crucial role of GDH1 in glutaminolysis in human cancer cells.
Furthermore, we demonstrated that GDH1 expression levels
correlate with progressive stages of breast cancer and lung
cancer by performing immunohistochemical staining (IHC) using
primary tissue microarray samples from breast and lung cancer
patients (Figures 1C and 1D, respectively). GDH1 expression
levels were significantly increased in the tumor samples from pa-
tients with advanced stages of breast or lung cancer compared
with adjacent normal tissues from the same patients or normal
tissues from individuals with no cancer.258 Cancer Cell 27, 257–270, February 9, 2015 ª2015 Elsevier Inc.GDH1 Is Important for Cancer Cell Proliferation and
Tumor Growth
To determine the role of GDH1 in cancer cell proliferation, we
generated a group of human cancer cell lines with stable knock-
down of GDH1. These included H1299 and MDA-MB231 tumor
cells, as well as human leukemia HEL and K562 cells. Nonmalig-
nant, proliferating human fetal lung fibroblast MRC-5 and human
keratinocyte HaCaT were included as controls. Stable knock-
down of GDH1 resulted in decreased cell number in all of the
cancer cell lines tested (Figure 2A), but not in control normal
proliferating cells (Figure 2B), suggesting a crucial role of
GDH1 in cancer cell proliferation. Similar results were obtained
from colony formation assay (Figure S1A available online) and
DNA-based cell proliferation assay (Figure S1B). Oxidative
stress and low glucose culture conditions but not hypoxic condi-
tions further attenuated cell proliferation uponGDH1 knockdown
in H1299 lung cancer cells (Figure 2C).
Moreover, we performed a xenograft experiment in which
nude mice were subcutaneously injected with H1299 cells
harboring an empty vector and H1299 cells with GDH1 knock-
down grown on the left and right flanks, respectively. We found
that GDH1 knockdown resulted in significantly reduced tumor
growth in most of the mice, with four of nine mice tumor free
compared with tumors derived from control cells with empty
vector (Figures 2D and 2E). These results together suggest that
GDH1 confers a proliferative advantage to cancer cells and tu-
mor growth.
GDH1 Is Critical for Redox Regulation, but Not
Bioenergetics or Anabolic Biosynthesis, in Cancer Cells
To decipher the role of GDH1 in bioenergetics, anabolic biosyn-
thesis, and redox homeostasis of cancer cells, we performed a
set of metabolic assays using lung cancer H1299 and breast
cancer MDA-MB231 cells with GDH1 knockdown. We found
that attenuation of GDH1 in cancer cells did not affect the intra-
cellular ATP levels compared with control cells harboring an
empty vector (Figure S2A). GDH1 knockdown cells showed
increased glucose uptake, glycolytic rates, and lactate produc-
tion but unaltered oxygen consumption rate compared with con-
trol cells (Figures S2B and S2C). In addition, intracellular ATP
level was significantly decreased in GDH1 knockdown cells
compared with control cells upon treatment with glycolytic inhib-
itor, 2-deoxyglucose (2-DG), or glucose deprivation, but not
when treated with oligomycin, an inhibitor of oxidative phosphor-
ylation (Figure S2D). These data together suggest that defective
glutaminolysis due to GDH1 knockdown allows cells to further
rely on glucose catabolism for bioenergetics. Moreover, GDH1
knockdown did not affect oxidative pentose phosphate pathway
(PPP) flux (Figure S2E) or the overall lipid or RNA biosynthesis
(Figures S2F and S2G). However, knockdown of GDH1 signifi-
cantly decreased glutamine-dependent RNA biosynthesis,
whereas such change of RNA synthesis was not comparable
to glucose-derived RNA synthesis (Figure S2G). In contrast,
GDH1 knockdown significantly attenuated intracellular ATP
levels as well as overall lipid and RNA synthesis levels in cells
under stress conditions, including low oxygen or low glucose
(Figures S2H–S2J), suggesting that GDH1 is important in
compensating glucose catabolism and oxidation in cells
under stress. Nevertheless, since cells with GDH1 knockdown
Figure 1. GDH1 Predominantly Regulates a-KG Production in Cancer Cells and Is Upregulated in Human Lung and Breast Cancers
(A) Intracellular a-KG levels were determined in human lung cancer H1299 and breast cancerMDA-MB231 cells with stable knockdown of GDH1, GOT2, or GPT2.
Expression of GDH1, GOT2, and GPT2 in H1299, and MDA-MB231 cells are shown by western blot analyses. b-actin was used as a loading control.
(B) Glutaminolytic rates in H1299 and MDA-MB231 cells were determined with stable knockdown of GDH1 or control cells harboring an empty vector. DON
(6-diazo-5-oxo-I-norleucine), glutamine antagonist, was used as a positive control. GDH1 expression is shown by western blotting. Data are mean ± SD from
three replicates of each sample, and p values were determined by a two-tailed paired Student’s t test for (A) and (B) (ns, not significant; *0.01 < p < 0.05; **0.001 <
p < 0.01).
(C and D) Immunohistochemistry analyses of GDH1 expression in groups of primary human tissue specimens. Tissue microarrays of breast ductal carcinoma (C)
and lung cancer (D) were obtained from US Biomax. Scale bars represent 50 mm. Data are mean ± SD; p values were obtained by ANOVA test (*0.01 < p < 0.05;
***p < 0.001).demonstrate reduced cell proliferation and tumor growth under
normal conditions, we hypothesized that other metabolic de-
fects such as redox metabolism changes might be responsible
for the proliferative disadvantage in cells conferred by GDH1
knockdown.
Indeed, we found that knockdown of GDH1 resulted in
increased mitochondrial ROS levels (Figure 3A, left) and intracel-
lular H2O2 levels (Figure 3A, right), while stress conditions
induced by H2O2 or glucose deprivation resulted in further
elevated ROS levels in GDH1 knockdown cells (Figure S2K). In
contrast, NADPH levels (Figure 3B, left) and the GSH/GSSG ratio
(Figure 3B, right) were significantly decreased in GDH1 knock-
down cells compared with control cells. These data togetherCsuggest that GDH1 is important for redox homeostasis in cancer
cells, most likely by regulating ROS levels. Consistently, treat-
ment with antioxidant N-acetylcysteine (NAC) in GDH1 knock-
down cells significantly rescued the increased ROS and reduced
cell proliferation due to GDH1 deficiency (Figure 3C). Such
rescue effects weremore apparent under oxidative stress condi-
tion induced by H2O2 (Figure 3C, upper). Next, we functionally
validated this in vivo by performing xenograft experiments.
Nude mice were subcutaneously injected with control H1299
cells harboring empty vector or GDH1 knockdown cells. NAC
at a concentration of 10 mg/ml was administered via drinking
water to half of the mice injected with GDH1 knockdown cells.
NAC treatment partially rescued the attenuated tumor growthancer Cell 27, 257–270, February 9, 2015 ª2015 Elsevier Inc. 259
Figure 2. GDH1 Is Important for Cancer Cell Proliferation and Tumor Growth
(A and B) Cell proliferation rates were determined by cell counting in H1299 andMDA-MB231 tumor cells (A, left), HEL and K562 leukemia cells (A, right) andMRC-
5 and HaCaT (B) with stable knockdown of GDH1 compared with control cells expressing an empty vector. Expression of GDH1 in cells transduced with GDH1
shRNA clones is shown by western blot analyses.
(C) Effect of GDH1 knockdown on cell proliferation rates were measured under stress conditions, including low oxygen (1% O2), low glucose (0.5 mM glucose),
and oxidative stress (15 mM H2O2).
(D) Effect of GDH1 knockdown on tumor growth potential of H1299 cell xenograft mice. (Left) Tumor sizewasmonitored every 2–3 days for 6weeks. The error bars
represent SEM. (Right) Tumor weights were examined at the experimental endpoint.
(E) (Left) Representative pictures of IHC staining to detect Ki-67 expression in tumors harvested from vector control group or GDH1 knockdown group. Scale bars
represent 50 mm. (Right) Representative dissected tumors and GDH1 expression in tumor lysates are shown. Data are mean ± SD from three replicates of each
sample except (D) and (E). p values were determined by a two-tailed Student’s t test for (C) and a two-tailed paired Student’s t test for (D) (ns, not significant;
**0.001 < p < 0.01).
See also Figure S1.of H1299 GDH1 knockdown cells in xenograft nude mice
(Figure 3D).
To determine whether GDH1 enzyme activity is important for
ROS regulation, we next tested whether rescue of reduced
intracellular levels of the GDH1 product, a-KG, could reverse
the elevated ROS level in GDH1 knockdown cells (Figure 3E).
Indeed, cell-permeable methyl-a-KG significantly rescued the
attenuated intracellular a-KG (Figure 3E, upper), elevated ROS
(Figure 3E, middle), and decreased cell proliferation (Figure 3E,
lower) levels in GDH1 knockdown cells. These data suggest
that GDH1 requires its enzyme activity to regulate ROS, which
contributes to redox homeostasis and cancer cell proliferation.
GDH1 Contributes to Redox Homeostasis in Part by
Regulating GPx Activity in Cancer Cells
To investigate how GDH1 regulates ROS levels in cancer cells,
we tested whether GDH1 knockdown attenuates any of the
known ROS scavenging enzymes, including GPx, GSR, thiore-
doxin reductase (TRX), SOD, CAT, and PRX. We found that
only GPx enzyme activity is significantly attenuated in GDH1260 Cancer Cell 27, 257–270, February 9, 2015 ª2015 Elsevier Inc.knockdown MDA-MB231 cells compared with control cells
harboring an empty vector (Figure 4A, left). Similar results were
obtained using lung cancer H1299 cells (Figure 4A, right).
To further substantiate that GDH1 controls ROS levels through
GPx in cancer cells, we first tested the effect targeting GPx on
cell proliferation and ROS level of cancer cells. Although GPx1,
GPx3, GPx4, GPx6, and GPx8 exist in human breast cancer
cell line MDA-MB231 (Figures S3A and S3B), GPx1 is the pre-
dominant isoform that contributes to GPx activity in cancer cells
(Figures S3C and S3D). Therefore, we assessed the impact of
targeting GPx1. RNAi-mediated downregulation of GPx1 effec-
tively decreased total GPx activity (Figure 4B, left). Moreover,
knockdown of GPx1 mimicked the effect of GDH1 knockdown,
leading to decreased cell proliferation and increased ROS (Fig-
ure 4B, middle and right). We next tested whether overexpres-
sion of active GPx1 can reverse the increased ROS levels and
attenuated cell viability in GDH1 knockdown cells. GPx1 is a se-
lenoprotein, which requires a selenocysteine insertion sequence
(SECIS) element to translate the UGA codon in the GPx1 gene as
selenocysteine (Walczak et al., 1998). We generated a GPx1
Figure 3. GDH1 Contributes to Redox Homeostasis in Cancer Cells
(A and B) Mitochondrial ROS and cellular H2O2 levels (A), NADPH levels andmitochondrial GSH/GSSG ratio (B) were determined in H1299 andMDA-MB231 cells
with GDH1 knockdown or control cells with an empty vector.
(C) H1299 cells with GDH1 knockdown were treated with antioxidant agent NAC (1 mM). ROS (upper) and cell proliferation (lower) were measured.
(D) NAC (10 mg/ml drinking water) was administrated in H1299 xenograft mice with GDH1 knockdown. (Upper left) Tumor growth was monitored. The error bars
represent SEM. (Upper right) Tumor weights were examined at the experimental endpoint. (Lower left) Representative pictures of Ki-67 IHC staining of tumor
samples. Scale bars represent 50 mm. (Lower right) GDH1 expression in tumor lysates is shown.
(E) H1299 cells were treated in the presence and absence of 0.5 mM methyl-a-KG. Intracellular a-KG level (upper), ROS production (middle), and proliferation
rates (lower) were determined as described above. Data aremean ± SD from three replicates except (D). p valueswere determined by a two-tailed Student’s t test
(ns, not significant; *0.01 < p < 0.05; **0.001 < p < 0.01).
See also Figure S2.construct with a 30UTR containing the SECIS element to express
GPx1 in cells (Figure 4C). We observed that stable overexpres-
sion of active GPx1 rescued the attenuated total GPx activity
in GDH1 knockdown cells, leading to increased proliferative
ability and decreased ROS compared with control GDH1 knock-
down cells (Figure 4D). We found that GPx1 colocalizes with
GDH1 in the mitochondria (Figures S3E–S3G) and GDH1
regulates GPx1 activity in the mitochondria of cancer cells
(Figure S3H).
GDH1 Controls Fumarate Level to Potentiate GPx
Activity
Wenext explored themolecular mechanism bywhichGDH1 reg-
ulates GPx activity. We found that GDH1 does not form a protein
complex with GPx1 (data not shown). We thus hypothesized that
GDH1 may indirectly regulate GPx activity and subsequent ROS
levels by controlling intracellular levels of a-KG. As shown in Fig-
ure 5A, treatment with methyl-a-KG fully rescued the attenuated
GPx activity in GDH1 knockdown cells. Next, we incubated pu-Crified active GPx1with physiological concentrations of a-KG (20–
80 mM) or other metabolite intermediates derived from a-KG
including fumarate (20–80 mM), succinate (200–500 mM), andma-
late (200–500 mM) to check whether these metabolites directly
affect GPx1 activity in vitro (Figure 5B), since each of these me-
tabolites was significantly decreased in cancer cells upon GDH1
knockdown (Figures 1A, 5C, S4A, and S4B, respectively). Inter-
estingly, activity of purified human GPx1 either from transient
expression in mammalian cells (Figure 5B, upper) or human
erythrocytes (Figure 5B, lower) was significantly increased
in vitro by fumarate but not the other metabolites. Moreover,
treatment with the GDH1 product methyl-a-KG rescued the
decreased fumarate in cancer cells, suggesting that GDH1 and
its product a-KG control intracellular fumarate levels (Figure 5C).
To examine whether fumarate binds to and activates GPx1, we
performed a radiometric metabolite-protein interaction analysis
using 14C-labeled metabolites incubated with GPx1 enriched
from cells. Labeled fumarate but not a-KG, succinate, or malate
was retained onGPx1, suggesting that fumarate directly binds toancer Cell 27, 257–270, February 9, 2015 ª2015 Elsevier Inc. 261
Figure 4. GDH1 Contributes to Redox Homeostasis in Part by Regulating GPx Activity in Cancer Cells
(A) Effect of GDH1 knockdown on the enzyme activity of GPx and other ROS scavenging enzymes, including GSR, TRX, SOD, CAT, and PRX inMDA-MB231 (left)
and H1299 (right) cells. Western blots displaying the expression of GPx1, GSR, TRX1, SOD2, CAT, PRX3, and GDH1 in cells with GDH1 stable knockdown or an
empty vector. b-actin was used as a loading control.
(B) Effect of GPx1 knockdown on total GPx activity (left), cell proliferation (middle), and ROS (right) in MDA-MB231 cancer cells. Knockdown efficiency of GPx1
was determined by western blotting. Cell proliferation rates and ROS levels were assessed by cell counting and carboxy-H2DCFDA detection, respectively.
(C) Induction of GPx1 expression in 293T cells transduced with a GPx1 expression construct harboring a 30UTR with a SECIS element that responds to selenite.
Expression of myc tagged GPx1 was determined by immunoblotting using anti-myc and anti-GPx1 antibodies.
(D) Effect of myc-GPx1 stable expression on the total cellular GPx activity (left), cell proliferation (middle), and ROS (right) in MDA-MB231 and H1299 cells with
stable knockdown of GDH1. Ten ng/ml selenite was added in the culture media for all the assays. GDH1 knockdown and myc-GPx1 expression is shown by
western blot analyses. Data are mean ± SD from three replicates. p values were determined by a two-tailed Student’s t test (*0.01 < p < 0.05; **0.001 < p < 0.01).
See also Figure S3.GPx1 (Figures 5D and S4C). The Kd value of the GPx1-fumarate
interactionwas calculated to be 75.52 ± 5.22 mM (Figure S4C). To
determine the selectivity of fumarate binding to GPx1, we gener-
ated a GPx1 mutant with substitutions at T143 and D144. These
residues are predicted to be critical for fumarate binding to GPx1
by a molecular docking study (Figure S4D). Mutational studies262 Cancer Cell 27, 257–270, February 9, 2015 ª2015 Elsevier Inc.demonstrated that GPx1 T143A/D144A (2A) was resistant
to fumarate binding and the enzyme activity was no longer
enhanced by fumarate (Figures S4E and 5E). This suggests
that the GPx1-fumarate interaction is required for fumarate
induced GPx1 activation. Furthermore, knockdown of succinate
dehydrogenase A (SDHA), which produces fumarate in the TCA
Figure 5. GDH1 Promotes GPx Activity by Controlling Intracellular Fumarate Level
(A) GPx activity in cancer cells with stable knockdown of GDH1 was determined in the presence or absence of cell-permeable methyl-a-KG.
(B) The activity of purified flag-GPx1 from 293T cells or endogenous GPx1 from human erythrocytes was examined in the presence of increasing concentrations
of a-KG, fumarate, succinate, or malate. Western blot analyses show GPx1 input for each sample.
(C) Effect of methyl-a-KG treatment on intracellular fumarate level in GDH1 knockdown cells.
(D) Flag-GPx1 was pulled down from transfected 293T cell lysates and incubated with 14C-fumarate or 14C-a-KG. The unbound metabolites were washed away
and retained fumarate or a-KG was measured using a scintillation counter. Western blot analysis shows GPx1 input for each sample.
(E) The activity of purified flag-GPx1 WT or fumarate binding-deficient mutant flag-GPx1 T143A/D144A (2A) from 293T cells was examined in the presence of
fumarate (80 mM). Western blot analysis shows GPx1 input for each sample.
(F) Intracellular fumarate levels (upper) and relative enzyme activity of endogenous GPx (lower) in GDH1 knockdown cells were determined in the presence or
absence of methyl-a-KG and SDHA siRNA. Knockdown of GDH1 and SDHA is shown by western blot analyses.
(G) Intracellular fumarate levels (upper), GPx activity (middle), and ROS levels (lower) in cancer cells with stable knockdown of GDH1 were determined in the
presence or absence of cell-permeable dimethyl-fumarate. Data are mean ± SD from three replicates. p values were determined by two-tailed Student’s t test
(ns, not significant; *0.01 < p < 0.05; **0.001 < p < 0.01).
See also Figure S4.
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Figure 6. Identification and Characterization of R162 as a Small Molecule Inhibitor of GDH1
(A) (Left) Schematic illustration of screening strategies used to identify lead compounds as GDH1 inhibitors. (Right) Structures of purpurin and its derivative R162.
(B) Activity of purified GDH1 in the presence of different concentrations of a-KG and purpurin (left) or R162 (right).
(C) Kd values were determined by tryptophan fluorescence binding assay. Purified GDH1 was incubated with increasing concentrations of purpurin (left) or R162
(right).
(D) GDH activity was determined in cancer cells treated with R162 (20 mM).
(E) Mitochondrial ROS levels were determined in H1299 and MDA-MB231 cells in the presence of R162.
(legend continued on next page)
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cycle abolished the rescue effect of methyl-a-KG in GDH1
knockdown cells (Figure 5F). Consistently, decreased fumarate
levels in GDH1 knockdown cells were rescued by cell-permeable
dimethyl-fumarate (Figure 5G, upper), leading to partially
rescued GPx activity and decreased ROS level in these cells
(Figure 5G, middle and lower, respectively). These data together
suggest that GDH1 plays an important role in redox regulation by
activating GPx1 through controlling intracellular levels of a-KG
and fumarate.
Identification and Characterization of R162 as a Small
Molecule Inhibitor of GDH1
Our finding that GDH1 is upregulated in human cancers and that
attenuation of GDH1 impacts cancer cell proliferation and tumor
growth implicates GDH1 as a promising anticancer target.
Currently, the only reported GDH1 inhibitor is epigallocatechin
gallate (EGCG), a polyphenol flavonoid isolated from green tea.
However, EGCG targets a group of enzymes that use NADPH
as a cofactor (Li et al., 2006, 2011a, 2011b). We thus designed
a series of screening assays to identify GDH1-selective inhibi-
tors. We identified a lead small molecule compound, purpurin,
as aGDH1 inhibitor from a library of 2,000 Food andDrug Admin-
istration-approved small molecule compounds (Figures 6A and
S5A–S5C). Purpurin demonstrated dramatic inhibitory effects
on the enzyme activity of recombinant, purified active GDH1 pro-
teins in an in vitro GDH activity assay with Ki and Kd 1.9 ± 0.26
and 11.46 ± 1.17 mM, respectively (Figures 6B and 6C, left).
Although purpurin showed dramatic inhibitory effect on GDH1
enzyme activity in vitro, the compound was not cell permeable
(Figure S5D). Therefore, we next identified the purpurin analog
R162 as a potent GDH1 inhibitor from a group of purpurin deriv-
atives (Figures S5E–S5G, 6B, and 6C, right). R162, which ismore
cell-permeable than purpurin due to its allyl group, demon-
strated more potent inhibitory effects on mitochondrial GDH ac-
tivity and elevated ROS levels in cancer cells (Figures 6D and 6E,
respectively). Purpurin specifically inhibits activity of GDH but
not other NADPH-dependent enzymes such as 6-phosphogluc-
onate dehydrogenase (6PGD) and fumarate hydratase (FH)
in vitro, whereas EGCG significantly affected activity of 6PGD
and FH in vitro (Figure S5H). Moreover, comparison of purpurin,
R162, and EGCG demonstrated that purpurin and its analog,
R162, are more potent and specific for GDH1 inhibition in vitro
and in cancer cells (Figures S5I–S5K).
To examine the interaction between GDH1 and R162, a
thermal melt shift assay was performed. Incubating GDH1 with
increasing concentrations of R162 raised the melting tempera-
ture (Tm) in a dose-dependent manner, suggesting that R162
directly binds to GDH1 (Figure 6F). In addition, in a competitive
binding assay where R162 was incubated with purified GDH1
protein in the presence of different concentrations of GDH1 sub-(F) Thermal shift melting curve of purified GDH1 incubated with increasing conce
are indicated.
(G) Lineweaver-Burk plot of GDH activity in the presence of increasing concentr
(H) Effects of methyl-a-KG treatment (1 mM) on intracellular fumarate level (upper
right) in R162-treated H1299 and MDA-MB231 cells were examined.
(I) Effect of NAC treatment (3 mM) on ROS level (upper) and cell proliferation (lower
determined by a two-tailed Student’s t test (*0.01 < p < 0.05; **0.001 < p < 0.01)
See also Figure S5.
Cstrate a-KG, the Lineweaver-Burk plot shows that R162 acts as a
mixed model inhibitor of GDH1 (Figure 6G).
We also found that inhibition of GDH1 activity by R162
treatment results in decreased intracellular fumarate levels,
attenuated GPx activity, increased ROS levels, and reduced
cell proliferation in H1299 and MDA-MB231 cells, which could
be significantly rescued by methyl-a-KG treatment (Figure 6H)
as well as by antioxidant NAC (Figure 6I). These data are essen-
tially consistent with the phenotypes observed in GDH1 knock-
down cells, suggesting that R162 targets GDH1 to disrupt redox
balance through GPx1 and inhibit cancer cell proliferation.
R162 dramatically attenuated cell viability in a group of human
lung cancer, breast cancer, and leukemia cell lines, but not in hu-
man proliferating cells, including human keratinocyte (HaCaT),
human fetal lung fibroblast (MRC-5), and human foreskin fibro-
blast cells (HFF), which serve as control proliferative human cells
(Figure 7A). Furthermore, inhibiting GDH1 by R162 also resulted
in decreased cell viability of primary leukemia cells from myeloid
leukemia patients, but did not affect cell viability of mononucleo-
cytes in peripheral blood samples from healthy human donors
(Figure 7B). These data suggest the antiproliferative potential
of R162 in human cancer cells with minimal toxicity.
Next we tested the in vivo efficacy of R162 in the treatment
of xenograft tumor mouse models. For initial in vivo toxicity
studies, 30 mg/kg/day of R162 was administered to mice for
30 days by intraperitoneal injection. The chronic R162 treatment
did not result in a significant histopathological change between
the vehicle-treated and R162-treated groups (Figure 7C), nor
altered complete blood counts, or hematopoietic properties
(Figure 7D), suggesting minimal toxicity of R162 in vivo. There-
fore, we performed an in vivo R162 treatment using H1299-
xenograft nude mice. A day after xenograft injection, mice
were divided into two groups (n = 8 per group) and treated
with either R162 (20 mg/kg/day) or control DMSO for 35 days.
R162 treatment resulted in significantly decreased tumor
growth and masses in mice compared with control mice (Fig-
ure 7E). Moreover, R162 effectively inhibited GDH1 activity in
resected tumors from xenograft nude mice (Figure 7F). These
results together suggest that R162 is a GDH1 inhibitor with
promising antiproliferative potential in cancer cells with minimal
toxicity in vitro and in vivo.
DISCUSSION
Our findings suggest a mechanism by which the mitochondrial
GDH1 contributes to redox homeostasis. GDH1 controls the
intracellular levels of its product a-KG and the subsequent meta-
bolic intermediate fumarate, which binds and activates the ROS
scavenging enzyme GPx1, providing metabolic advantages to
cancer cell proliferation and tumor growth (Figure 8). Althoughntrations of R162. Melting temperature (Tm) of DMSO control and 50 mM R162
ations of R162 and a-KG.
left), GPx activity (lower left), ROS level (upper right), and cell proliferation (lower
) in R162-treated cells. Data aremean ± SD from three replicates. p values were
.
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Figure 7. R162 Inhibits Cell Proliferation and Tumor Growth Potential of Human Cancer Cells
(A) Cell viability of diverse human tumor and leukemia cells in the presence of R162. Control cells include HaCaT, MRC-5, and HFF.
(B) Effect of R162 treatment on cell viability of human primary leukemia cells from patients with myeloid leukemia. Peripheral blood cells from healthy donors were
included as controls. BM, bone marrow; PB, peripheral blood; AML, acute myeloid leukemia; CML, chronic myeloid leukemia.
(C) Histological analysis of hematoxylin-eosin stained tissue sections of representativemice in R162 or vehicle control-treated group. Scale bars represent 50 mm.
Mice were treated with R162 (30 mg/kg/day) for 30 days.
(D) Hematology blood test of R162 or vehicle control-treated mice.
(E) Effect of R162 administration on tumor growth in H1299 xenograft mice model. (Left) Tumor growth was monitored. The error bars represent SEM. (Middle)
Tumor weight was examined at the experimental endpoint. (Right) Representative pictures of Ki-67 IHC staining of tumor samples from control or R162 treatment
group. Scale bars represent 50 mm.
(F) GDH1 protein and activity levels were determined in dissected tumor samples. Representative pictures of dissected tumors are shown. GDH1 expression in
tumor lysates is shown by western blotting. Data are mean values ± SD from three replicates except (C) and (E). p values were determined by a two-tailed
Student’s t test (*0.01 < p < 0.05).three enzymes, including GDH1, GOT2, and GPT2, are reported
to convert glutamate to a-KG (Kovacevic, 1971; Quagliariello
et al., 1965), our results demonstrate that GDH1 plays a predom-
inant role in maintaining the physiological levels of a-KG in can-
cer cells. GDH1 may also play a critical role in a-KG-dependent266 Cancer Cell 27, 257–270, February 9, 2015 ª2015 Elsevier Inc.biological functions, including not only the TCA cycle but also
epigenetic regulations involving diverse a-KG-dependent en-
zymes such as histone and DNA dioxygenases that regulate
genome-wide histone and DNA methylation (Loenarz and Scho-
field, 2008; Simmons et al., 2008).
Figure 8. Proposed Model for the Role of GDH1 in Cancer Metabolism
Upregulated GDH1 in cancer cells is critical to maintain the physiological levels of a-KG and consequently fumarate. Fumarate may in turn bind to and activate the
ROS scavenging enzyme GPx to regulate redox homeostasis, which provides a proliferative advantage to cancer cells and tumor growth. In contrast, sup-
pression of GDH1 decreased a-KG and fumarate levels, leading to reduced GPx activity and subsequently elevated ROS that attenuates cancer cell proliferation
and tumor growth.Emerging evidence has demonstrated the importance of
glutamine as an alternative carbon source for both bioenergetics
and anabolic biosynthesis in addition to glucose. Consistently,
our results showed that suppression of GDH1 resulted in
decreased glutaminolysis, which renders cancer cells more
dependent on glycolysis and more sensitive to stress conditions
such as glucose deprivation, but not low oxygen. Moreover,
although GDH1 deficiency resulted in decreased biosynthesis
of lipids and RNA derived from glutamine, such changes in
biosynthesis are dispensable to cancer cells when glucose
dependent biosynthesis is predominant under normal, stress-
free conditions. These metabolic changes are either advanta-
geous (increased glycolysis) or dispensable (biosynthesis) to
cancer cells. However, the GDH1 knockdown cells still showed
decreased cell proliferation and tumor growth, suggesting that
other severe metabolic defects due to GDH1 deficiency eventu-
ally overshadow these changes. Our findings showing that
GDH1 regulates redox homeostasis through GPx1 shed insights
into the current understanding of the biological functions of
GDH1 and reveal a distinct crosstalk between glutaminolysis
and redox maintenance.
Moreover, our finding that fumarate binds to and activates
GPx1 provides another example to support an emerging mech-
anism in which metabolic intermediates may function as
signaling molecules to allow crosstalk between metabolic and
cell signaling pathways (Hitosugi et al., 2012; Sanders et al.,
2007). A recent report demonstrates that FH loss increases
fumarate levels and results in mitochondrial ROS activation in
FH-deficient renal carcinoma cells (Sullivan et al., 2013). This im-
plies that the role of fumarate may depend on cancer type and
discrete TCA cycle conditions, such as intracellular fumarate
levels. Our findings, along with others, showcase the compli-
cated signaling properties in cancer cells that coordinate meta-
bolic and cell signaling networks to provide ultimately optimized
proliferative advantages to cancer cells. Future studies are war-
ranted to decipher the structural basis by which fumarate regu-
lates GPx activity.
Targeting GDH1 with shRNA or a small molecule inhibitor
R162 led to reduced cancer cell proliferation and tumor growth.CTreatment with the cell permeable GDH1 product, methyl-a-KG,
significantly rescued these phenotypes. However, rescue of
a-KG level by methyl-a-KG significantly but not completely
reversed decreased cell proliferation in GDH1 knockdown cells,
suggesting that the effects of GDH1 on cell proliferation are
dependent not only on enzyme activity but also on protein level.
In addition, antioxidant NAC treatment reversed ROS levels to
that of control cells, but could not completely rescue the reduced
cell proliferation or tumor growth in GDH1 knockdown cells. This
suggests that GDH1 regulates not only redox status but also
other cellular properties that contribute to the regulation of can-
cer cell proliferation and tumor growth. Future studies are war-
ranted to further investigate the GDH1 enzyme-independent
signaling mechanism, which confers cancer cell proliferation
and tumor growth.
Recent studies have suggested that targeting the RhoGTPase
signaling-dependent GLS, the first enzyme in the glutaminolysis
process that converts glutamine to glutamate, effectively sup-
presses the growth of cancer cells (Wang et al., 2010). Inhibition
of GLS with another GLS inhibitor bis-2-[5-phenylacetamido-
1,2,4-thiadiazol-2-yl] ethyl sulfide, also attenuated growth of gli-
oma cells with mutant IDH1 (Robinson et al., 2007; Seltzer et al.,
2010). Our studies show that attenuation of GDH1, commonly
upregulated in human cancers, specifically reduced breast can-
cer, lung cancer, and leukemia cell proliferation but not that of
nonmalignant human proliferating cells. Here we report that
targeting GDH1 regulates both glutaminolysis and redox balance
in cancer cells, suggesting GDH1 as an attractive anticancer
target. Although the antioxidant polyphenol flavonoid, EGCG,
is reported to inhibit GDH1 activity, it is a general inhibitor of
NADPH-dependent enzymes. Our small molecule R162 has
promising efficacy in inhibiting cancer cell proliferation as well
as primary leukemia cells from patients with minimal cytotoxic
effects to human cells. R162 also has promising efficacy in vivo
with minimal toxicity. Our present studies provide a proof of prin-
ciple that GDH1 could be a promising alternative therapeutic
target for the clinical treatment of human cancers that rely heavily
on glutamine metabolism. Further in vivo toxicity of these small
molecule GDH1 inhibitors in metabolically active organs suchancer Cell 27, 257–270, February 9, 2015 ª2015 Elsevier Inc. 267
as brain, heart, and liver needs to be tested, and detailed phar-
macokinetics studies will be needed. These well-characterized
GDH1 inhibitors will also be powerful chemical tools to further




Lentiviral short hairpin RNA (shRNA) targeting GDH1, GOT2, and GPT2 and
GDH1 image clone were purchased from Open Biosystems. SDHA siRNA
was from QIAGEN. Human GPx1 with 30UTR region was myc or flag tagged
by PCR and subcloned into pLHCX-derived Gateway destination vector. The
GPx1 variant was generated by Site-directed mutagenesis kit (Aligent
Technologies). Mitochondria were isolated from cells using a mitochondria
isolation kit (Pierce). Purified GDH from human erythrocytes was obtained
from Sigma-Aldrich. 14C-fumaric acid (60 mCi/mMol) was obtained from
Moravek Biochemicals, and 14C-ketoglutaric acid (58.7 mCi/mMol) was from
Perkin Elmer. All chemicals were purchased from Sigma-Aldrich unless
specifically indicated.
Antibodies
Antibodies against GDH1, GOT2, GPT2, GPx1, PRX3, and Ki-67 were pur-
chased from Abcam. Anti-CAT, anti-TRX1, anti-SDHA, and anti-myc anti-
bodies were obtained from Cell Signaling Technology. Antibodies against
GSR and SOD2 were obtained from Santa Cruz Biotechnology and BD Biosci-
ences, respectively. Anti-FLAG and anti-b-actin antibodies were obtained
from Sigma-Aldrich.
Cell Culture
H1299, A549, HEL, KG1a,Molm14, K562 cells were cultured in RPMI 1640me-
dium with 10% fetal bovine serum (FBS). 293T, MDA-MB231, SKBR3, HaCaT,
HFF, and MRC-5 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% FBS. Lentivirus production, cell infection for RNAi and pro-
tein overexpression in human cells and stable cell selection were described
previously (Jin et al., 2013).
Enzyme Activity Assays
GDH enzyme activity assay was performed as previously described (Zaganas
et al., 2002). Briefly, 20 mg of total cell lysates or 100 ng of purified GDH1 was
added to the reaction mixture containing 50 mM triethanolamine (pH 8.0),
100 mM ammonium acetate, 100 mMNADPH, and 2.6 mM EDTA. The reaction
was initiated by adding a-KG, and the activity was assessed by monitoring the
oxidation of NADPH as a decrease in absorbance at 340 nm. GPx, SOD, TRX,
GSR, and CAT enzyme activities were determined by using commercially
available kits from Biovision according to the manufacturer’s instructions.
PRX enzyme activity was assayed by coupling its activity to oxidation of
NADPH via TRXs (Nelson and Parsonage, 2011).
Glutaminolysis Rate Measurement
Glutamine oxidation assay measuring 14CO2 from
14C glutamine was used to
determine glutaminolysis rate. Briefly, cells were seeded on 6-cm dishes that
were placed in a sealed 10-cm dish. Cells were incubated with 4 mCi/ml of
[U-14C] glutamine for 4 hr, and the reaction was stopped by the addition of
200 ml of 70% perchloric acid, which also released CO2; 0.5 ml of 3 M NaOH
was injected to a cup placed next to the 6-cm dish to absorb all the released
CO2 from the cells and after 12 hr incubation and 20 ml of NaOH was subjected
to liquid scintillation counting.
Intracellular ATP, Lactate Production, and Oxygen Consumption
Assays
Intracellular ATP concentration was measured by using an ATP biolumines-
cent somatic cell assay kit (Sigma-Aldrich); 5 3 105 cells were suspended in
ultrapure water. The reaction was initiated by adding ATP enzyme mix to the
cell suspension, and the luminescence was recorded by spectrofluorometer
(Molecular Probe). Cellular lactate production was measured with a fluores-
cence-based lactate assay kit (MBL). Plain phenol red-free RPMI medium268 Cancer Cell 27, 257–270, February 9, 2015 ª2015 Elsevier Inc.was added to subconfluent cells for 1 hr, and the media were assessed for
lactate level. The values were normalized with cell number. Oxygen consump-
tion rates were measured using a clark-type microcathode oxygen electrode
attached to a 782 oxygen meter (Strathkelvin Instruments).
Intracellular ROS, NADPH Level, and GSH/GSSG Ratio
Measurements
Total intracellular ROS was determined by staining the cells with carboxy-
H2DCFDA (Invitrogen), and mitochondrial ROS level was determined
by using a specific mitochondrial H2O2 probe, MitoPY1 (Sigma) as previously
described (Dickinson and Chang, 2008; Dickinson et al., 2013); 2 3 105
cells were incubated with 10 mM carboxy-H2DCFDA or 10 mM of MitoPY1 for
30 min at 37C. Cells were washed and analyzed by flow cytometry (BD
FACSCanto). Intracellular NADPH level and GSH/GSSG ratio were determined
using fluorimetric SensoLyte NADP/NADPH Assay (AnaSpec) and GSH/
GSSG-Glo (Promega), respectively.
Intracellular Metabolite Measurements
The intracellular levels of a-KG, fumarate, succinate, and malate were deter-
mined by using commercial kits (Biovision). Briefly, 23 106 cells were homog-
enized in PBS. The supernatant was collected, and proteins were removed by
using 10 KD Amicon Ultra Centrifugal Filters (Millipore). The flow-through con-
taining themetabolites was used for the measurement of a-KG, fumarate, suc-
cinate, and malate, following the manufacturer’s instructions.
Radiometric 14C-Fumarate/14C-a-KG-GPx1 Binding Assay
Bead-bound flag-GPx1 purified from transfected 293T cell lysates was
washed with Tris-buffered saline (TBS) buffer (50 mM Tris, 150 mM NaCl
[pH 7.5]), followed by incubation with 0.12 mCi 14C-fumarate or 14C-a-KG for
30 min in TBS buffer. The beads were then washed with TBS buffer. The
bead-bound GPx1 protein was eluted with 10 mg flag peptides, and radioac-
tivity was detected by liquid scintillation counting.
Cell Proliferation Assay
53 104 adherent cells or 13 105 leukemia cells were seeded in six-well plate,
and cell numbers were determined by trypan blue exclusion using TC10
automated cell counter (Bio-Rad). For a-KG, NAC, and R162 treatment exper-
iments, cells were treated with different concentrations of a-KG, NAC, and
R162, followed by cell counting as mentioned above.
Xenograft Studies
Animal experiments were performed according to protocols approved by the
Institutional Animal Care and Use Committee of Emory University. Nude mice
(athymic nu/nu, female, 4–6 weeks old; Harlan) were subcutaneously injected
with 13 107 H1299 cells harboring empty vector on the left flank, and cells with
stable knockdown of GDH1 on the right flank, respectively. For theNAC rescue
experiment, mice of the NAC rescue group were treated with NAC drinking
water at 10 mg/ml from 3 days after H1299-GDH1 shRNA cells injection for
42 days. To evaluate the efficacy of R162, the drug was administered from a
day after H1299 cells injection by daily intraperitoneal injection of 30 mg/kg
for 35 days. Fifty percent of DMSO in PBS was as a diluent control. Tumor
growth was recorded by measurement of two perpendicular diameters of
the tumors, and tumor size was calculated using the formula 4p/3 3 (width/
2)2 3 (length/2). The tumors were harvested and weighed at the experimental
endpoint. Tumor proliferation was determined by Ki-67 IHC staining.
Drug Screening Using In Vitro GDH Assay
To screen potential GDH1 inhibitors, in vitro GDH1 activity assay was per-
formed as described above in presence of compounds (10 mM) using GDH1-
overexpressing 293T cell lysates or purified GDH (Sigma-Aldrich). Detailed
screening strategy and results are shown in Figure S7.
GDH1 Enzyme Kinetics
Purified GDH1 (2 mM) was incubated with different concentrations of purpurin
or R162 in 50 mM Tris-Cl buffer (pH 7.5), and intrinsic tryptophan fluorescence
(Ex:280 nm/Em:350 nm) was measured for Tryptophan fluorescence binding
assay. Nonlinear regression analysis was performed using Prism 6 (GraphPad)
to calculate dissociation constant (Kd). Inhibition constants (Ki) of purpurin and
R162 were determined by GDH activity assay with different concentrations of
substrate, a-KG, and computed by using Prism 6 (GraphPad).
Thermal Shift Assay
Thermal shift assay was performed using the Protein Thermal Shift Dye Kit (Life
Technologies). Ten micromolar of purified GDH were incubated with different
concentrations of R162, and protein-drug mixture was added to the reaction
mixture. The fluorescence was recorded using Real-Time PCR Systems
(Applied Biosystems), and data were analyzed using Protein Thermal Shift
Software v1.0 (Life Technologies).
Tissue Microarray Analysis
Paraffin-embedded breast cancer and lung cancer tissue microarrays were
obtained from US Biomax. IHC analysis of GDH1 expression was performed
according to the protocol described previously (Li et al., 2013). Approval
of use of human specimens was given by the Institutional Review Board
of Emory University. All clinical samples were collected with informed
consent under Health Insurance Portability and Accountability Act-approved
protocols.
Statistical Analysis
Statistical analysis and graphical presentation was performed using Prism 6
(GraphPad). Data shown are from one representative experiment of multiple
independent experiments and are given as mean ± SD, except for tumor
growth curves, which represent mean ± SEM. Statistical analysis of signifi-
cance was based on the one-way ANOVA for Figures 1C and 1D and two-
tailed Student’s t test for all the other figures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
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